BMO Capital initiated coverage of Axsome Therapeutics Inc. on July 21, 2026. The firm issued an Outperform rating for the stock. Analysts set a price target of $310. This target suggests significant upside from the previous closing price of $221.64.
Regulatory filings released the same day revealed Fifth Third Bancorp increased its investment in the company. The bank boosted its holdings by 554.6% during the first quarter. It acquired an additional 13,737 shares to reach a total of 16,214 shares. The position was valued at approximately $2.74 million at the time of filing.